Aclaris Therapeutics entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company expects to raise approximately $46.7 million in net proceeds after deducting underwriting discounts, commissions, and other estimated expenses.
Key Details
- Offering Structure: The offering includes 7,785,714 shares of common stock at a price of $3.50 per share and pre-funded warrants to purchase 6,500,000 shares of common stock at $3.49999 per warrant.
- Financials: The offering is expected to generate net proceeds of approximately $46.7 million for the company.
- Timeline & Underwriters: The agreement was signed on October 27, 2026, with the offering expected to close on October 28, 2026. Leerink Partners LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. are acting as representatives of the underwriters.
- Warrant Terms: The pre-funded warrants have a minimal exercise price of $0.00001 per share, are exercisable immediately upon issuance, and do not expire.